瑞康醫藥(002589.SZ):擬以約2.3億元收購天津國慧大健康38.4%股權
格隆匯2月17日丨瑞康醫藥(002589.SZ)公佈,公司擬使用自有資金向煙台慧爍企業管理合夥企業(有限合夥)收購其持有的天津國慧大健康科技有限公司(簡稱“標的公司”)38.39992%的股權,以北京北方亞事資產評估事務所(特殊普通合夥)2022年1月28日出具的《瑞康醫藥集團股份有限公司擬股權收購涉及的天津國慧大健康科技有限公司股東全部權益價值項目資產評估報吿》(北方亞事評報字[2022]第01-042號)作為交易依據,經雙方協商一致同意,標的股權對應的交易對價金額約為2.30億元,占上一年度經審計淨資產的3.08%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.